Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Toboni

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Journal of the National Cancer Institute|February 18, 2026
Approaches to optimize the benefits of immunotherapy and immunotherapy combinations across endometrial cancer typesBradley R Corr, Kara D Romano, Michael D Toboni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2024
Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene AlterationsMoh'd M Khushman, Michael D Toboni, Joanne Xiu, et al.
Cancers|December 10, 2021
Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous CancerMichael D Toboni, Elena Lomonosova, Shaina F Bruce, et al.
Molecular Cancer Research : MCR|October 21, 2021
GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication StressMary M Mullen, Elena Lomonosova, Michael D Toboni, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Journal of the National Cancer Institute|February 18, 2026
Approaches to optimize the benefits of immunotherapy and immunotherapy combinations across endometrial cancer typesBradley R Corr, Kara D Romano, Michael D Toboni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 13, 2024
Differential Responses to Immune Checkpoint Inhibitors are Governed by Diverse Mismatch Repair Gene AlterationsMoh'd M Khushman, Michael D Toboni, Joanne Xiu, et al.
Cancers|December 10, 2021
Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous CancerMichael D Toboni, Elena Lomonosova, Shaina F Bruce, et al.
Molecular Cancer Research : MCR|October 21, 2021
GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication StressMary M Mullen, Elena Lomonosova, Michael D Toboni, et al.
Pageof 3